Overview of Celol-D3

What is Celol-D3: Definition and Drug Type

Property	Description
Active ingredient	Calcitriol, Elemental Calcium, DHA, EPA, Folic Acid, Methylcobalamin, Disodium Tetraborate
Form	Soft Gelatin Capsule (Oral)
Pharmacological class	Nutritional Supplement, Agents Affecting Bone Metabolism, Haematinics
Common use	Systemic nutritional and skeletal support
Origin	Combination of synthetic and naturally derived components

Celol-D3 is a highly specific, orally administered Nutritional Supplement defined as a Fixed-dose Combination product. It is officially classified within the broad category of Vitamin D analogs and is recognized as an agent supporting Bone Metabolism. Calcitriol is the active, hydroxylated form of Vitamin D3 that regulates calcium and phosphorus. The preparation is provided in a Soft Gelatin Capsule format, which is designed for efficient Oral consumption and is clinically recognized for its superior bioavailability compared to some other forms. This multi-component structure, which includes essential vitamins and fatty acids alongside minerals, distinguishes it from simpler single-entity agents.

The Unique Multi-Component Composition of Celol-D3

Celol-D3 is a complex formulation containing seven distinct Active ingredient(s). The preparation is a blend of Synthetic components, such as the active B-vitamins and Calcitriol, and naturally Derived elements like the Omega-3 Fatty Acids (DHA and EPA), which are essential nutrients commonly sourced from fish oil. The inclusion of Methylcobalamin, the metabolically active form of Vitamin B12, is a differentiating feature, often preferred over less active forms for supporting neurological function.

General Purpose and High-Level Action

The general purpose of Celol-D3 is to provide fundamental Systemic support by addressing concurrent nutritional deficits, making it a typical choice for elderly individuals or patients requiring enhanced skeletal and nerve maintenance. The formulation is primarily designed to facilitate efficient calcium absorption and aids in bone mineralisation, utilizing the active metabolite Calcitriol to regulate calcium levels. By also incorporating Haematinics and Omega-3 Fatty Acids, the product broadens its action to support vital neurological functioning and cellular health.

Regulatory References

What side effects are possible with Celol-D3?

Possible Side Effects and Safety Information

The safety profile for Celol-D3 is primarily governed by the risk associated with its most active component, Calcitriol (the active Vitamin D metabolite), and Elemental Calcium. The principal safety concern, classified as Very Common in regulatory documents, is the development of Hypercalcemia (elevated calcium levels in the blood), which is a direct consequence of the drug's effect on calcium absorption and metabolism.

Adverse reactions are officially grouped by the affected System-Organ Class (SOC), including the Metabolic and Nutritional Disorders, Gastrointestinal Disorders, and Renal and Urinary Disorders.

Frequency of Adverse Reactions

Classification	Example Reactions	Affected Systems
Very Common	Hypercalcemia	Metabolic/Nutritional
Common	Hypercalciuria, Headache, Nausea, Rash	Renal/Urinary, Nervous, GI, Skin
Uncommon	Decreased appetite, Vomiting	GI, Metabolic

Documented Safety Patterns

The official labeling notes that adverse effects, particularly Hypercalcemia, may appear or intensify during the initial phase of therapy or following dose adjustments. This time-related pattern necessitates close monitoring of serum calcium and phosphorus levels.

Severe or uncontrolled Hypercalcemia is officially documented as a Serious Adverse Reaction that can lead to long-term consequences, including the development of Nephrocalcinosis (calcium deposits in the kidneys) and Generalized Vascular Calcification.

Safety notes also indicate caution for special populations, such as elderly patients and individuals with renal impairment, who require enhanced monitoring. The preparation is formally contraindicated in patients with pre-existing Hypercalcemia or documented Vitamin D Toxicity.

Overdose and Emergency Response

The official overdose profile for Celol-D3 is defined by the high risk of hypercalcemia (abnormally high calcium levels) stemming from its Calcitriol and Elemental Calcium components. The progressive overdosage of this vitamin D metabolite can be severe and necessitates emergency attention.

Documented Manifestations

Overdose presentations are formally documented to include early, acute symptoms such as anorexia, nausea, vomiting, asthenia (weakness), and headache. If hypercalcemia is sustained or chronic, more serious systemic signs may occur, including polyuria, dehydration, and hypertension.

Severe Outcomes and Emergency Action

Untreated hypercalcemia is a medical emergency that can lead to life-threatening outcomes, including severe renal impairment and dangerous cardiac arrhythmias. The regulatory labeling mandates that a patient seek immediate medical attention or contact emergency services immediately upon the first signs of suspected overdose or confirmed hypercalcemia.

Supportive Management

As no specific antidote is known, management is strictly supportive. This procedure requires the immediate discontinuation of the medication and any co-administered calcium supplements. To ensure safety, hospital monitoring may be required, involving repeated checks of serum calcium and renal function until levels stabilize and normalize.

Therapeutic Uses of Celol-D3

What Celol-D3 Treats: Main Uses and Benefits

Celol-D3 is a fixed-dose combination generally applied to offer systemic nutritional and structural support across clinical areas where concurrent deficiencies often occur: bone health and neurological maintenance.

Managing Chronic Bone Loss and Skeletal Weakness

This therapy is commonly used to help manage conditions presenting with systemic or localized discomfort marked by compromised skeletal integrity, including osteopenia and established osteoporosis, particularly in older adults and postmenopausal women. The therapy is considered relevant for managing deficits that lead to low bone mineral density. This helps address symptom clusters related to skeletal weakness to support bone mineralization and support bone strength. Indications may be part of symptomatic management for hypocalcemia and deficiency-related bone disorders and skeletal fragility. Vitamin D analogs are relevant for easing low levels of calcium and bone disease. This provides supportive relief when symptoms interfere with routine activities due to skeletal fragility.

Addressing Multi-Nutrient Deficits and Nerve Health

Celol-D3 is relevant in situations where patients experience concurrent nutritional deficiencies (Vitamin D, Calcium, B12, Folic Acid) which can create noticeable physiological strain. The inclusion of key nutrients helps address symptom clusters related to systemic imbalance, such as deficiency-related fatigue and mild nerve-related issues (neuropathy). The product helps manage symptoms that interfere with daily functioning and contributes to easing the overall symptom load in situations where patients experience systemic or neurological discomfort.

“This combination therapy may be applied to offer supportive relief that helps patients cope more steadily with symptom fluctuations arising from core nutritional and structural deficits.”

Quick Fact: Relief for Systemic Nutritional Deficiencies Celol-D3 is applied when appropriate for the management of chronic conditions characterized by co-existing low levels of active Vitamin D, Calcium, Vitamin B12, and Folic Acid.

Regulatory References

NIH MedlinePlus overview on Calcitriol

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Celol-D3 — Official Regulatory Information

The eligibility for Celol-D3 is strictly determined by official regulatory documents based on metabolic status and pre-existing health conditions, primarily due to the potent Calcitriol and Calcium components.

Absolute Contraindications (Must Not Use)

Classification	Population/Condition
Metabolic State	Hypercalcemia or confirmed Vitamin D Toxicity
Allergy	Known Hypersensitivity to Calcitriol, any Vitamin D analog, or any excipient in the formulation

Restricted or Conditional Use

Use of Celol-D3 requires caution and close monitoring in specific populations:

Severe Organ Impairment: Patients with Severe Renal Impairment must be closely monitored for serum calcium and phosphate levels.
Comorbidities: Use is restricted in patients with Sarcoidosis or a history of Nephrolithiasis (kidney stones).
Drug Combination: Patients concurrently taking Digitalis/Digoxin require caution due to the risk of Celol-D3-induced hypercalcemia potentially leading to cardiac arrhythmias.

Age and Reproductive Eligibility

Adults and Older Adults: Use is established, though older adults require caution and monitoring.
Pediatric Patients: Use is generally Not Recommended unless explicitly for specific, labeled therapeutic indications.
Pregnancy and Lactation: Use is typically Not Recommended and requires strict monitoring due to the potential risk of hypercalcemia in the mother or infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several clinically significant interaction patterns based on the active components of Celol-D3 (Calcitriol, Elemental Calcium, and Omega-3 fatty acids).

Contraindicated Combinations

Co-administration with other Vitamin D analogs or pharmacologic doses of Vitamin D is contraindicated due to the additive risk of hypercalcemia. Separately, the calcium component is strictly contraindicated for co-administration with intravenous Ceftriaxone in neonates (age le 28 days) due to the risk of precipitation.

Exposure-Altering and Pharmacodynamic Effects

The Elemental Calcium component can reduce the systemic exposure of certain orally administered drugs, including Tetracycline and Fluoroquinolone antibiotics, and Levothyroxine, through a mechanism of binding (chelation) in the gut. To mitigate this interaction, these medications require a timing separation of at least two to six hours from the administration of Celol-D3.

Pharmacodynamically, the risk of cardiac arrhythmias is potentiated when the Calcitriol and Calcium components are combined with Cardiac Glycosides (e.g., Digoxin). Additionally, the Omega-3 fatty acids (DHA/EPA) may prolong bleeding time, which is relevant when co-administered with anticoagulants or anti-platelet agents.

Metabolic interactions are documented with certain anticonvulsants, such as Phenytoin and Barbiturates, which can increase the breakdown of Calcitriol, potentially decreasing its effect. Concomitant use with Magnesium-containing antacids should be avoided due to the risk of hypermagnesemia.

Mechanism of Action

Celol-D3 operates by modulating specific biological processes, engaging defined core mechanisms. The drug's mechanism of action is centered on well-defined signaling pathways, resulting in the modulation of dysregulated activity.

Selective Receptor Engagement and Signal Initiation

Celol-D3 functions as a selective agonist at a specific class of X-type receptors located on key regulatory cells. This binding initiates a specific intracellular signaling cascade, which represents the fundamental mechanistic sequence. This focused engagement modulates the earliest molecular steps that influence subsequent systemic physiological effects.

Modulating Cascade Propagation and Humoral Control

Following receptor activation, Celol-D3's mechanism alters the release and concentration of key chemical mediators (Mediator Y) within the local environment. This interference in the humoral signaling process contributes to the dampening of pathway activity escalation. This results in a modification of the activity state within targeted pathways, corresponding to a reduced effect of excessive mediator activity.

Normalization of Dysregulated System Activity

The cumulative mechanistic action results in the modulation of overactive or underactive physiological responses within the targeted regulatory system (System Z). By influencing the kinetics of the signaling cascade, Celol-D3's mechanism modifies the activity of overactive processes, resulting in alterations to the physiological activity profile of the system.

Dosage and Administration Information

How to Use Celol-D3

The administration of Celol-D3 is governed by official protocols designed for chronic management of metabolic deficits, defining its use as an Oral Soft Gelatin Capsule. The standard initial daily dose for the Calcitriol component is 0.25 micrograms (mcg), typically taken once a day. This frequency may be adjusted to an every other day schedule in specific clinical scenarios where serum calcium levels are near normal.

Effective use is constrained by the requirement for adequate daily intake of elemental calcium (e.g., 600 mg to 1300 mg), making co-intake a crucial administrative condition. The medicine is often specified for administration once a day in the morning for consistent management. Specific dosing regimens, starting at 0.25 mcg daily, are formally established for populations such as pediatric patients and those with Chronic Renal Failure.

Dose adjustment is a slow process; the protocol mandates that any change in dosage—which may increase the maintenance dose up to 1.0 mcg daily—must only occur at extended intervals of 4 to 8 weeks to accurately assess the biochemical response.

The procedural structure requires a rapid response to specific laboratory values. The dose must be immediately withheld if hypercalcemia or a serum Calcium imes Phosphate product exceeding 70 mg^2/ dL^2 occurs. Once calcium levels return to the normal range, the medicine is restarted at a lower dose than the previous administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Celol-D3

Evidence for Managing Skeletal Weakness and Bone Loss

Research exploring this combination medicine has focused on its primary components, Calcitriol and Elemental Calcium, and how they are studied in clinical contexts marked by functional limitations and conditions like osteoporosis or low bone mass. The body of evidence includes multiple Randomized Controlled Trials (RCTs) and scientific reviews that research examined regarding the combination's primary components, with studies exploring Bone Mineral Density (BMD) and fracture incidence. These trials typically included patient groups such as older adults and postmenopausal women with confirmed low bone density.

Findings from the research describe patterns observed in the studies related to data related to measured outcomes in bone mineral density compared to control groups receiving inactive substances. Some large-scale studies and scientific reviews have highlighted changes measured during the study period, including data related to the frequency of fractures that was observed in some studies associated with the core components.

What remains uncertain is the full research profile of the complete seven-component Celol-D3 formulation itself; evidence is largely based on studies of its individual components or subsets. Long-term effects are not fully established regarding the sustained changes in fracture outcomes that was observed in some studies over many years.

Evidence for Addressing Multi-Nutrient Deficits and Nerve Health

Research has also explored whether the components of Celol-D3—specifically Methylcobalamin, Folic Acid, DHA, and EPA—are relevant in patient populations with concurrent nutritional deficiencies and associated nerve-related symptoms. The studies monitored outcomes related to systemic or functional imbalance and outcomes describing episodic or acute changes in symptoms. Researchers used RCTs and other forms of research exploring short-term symptom changes, focusing on patient cohorts with low vitamin status.

Certainty remains low regarding the specific overall effects of combining all seven nutrients together, as comparative evidence is lacking for the fixed-dose combination. The clinical relevance of the reported changes in nutrient levels for outcomes reflecting daily functioning is still uncertain, as these changes do not always directly correspond to measurable differences in patient daily functioning.

What is Still Uncertain About Celol-D3

Evidence is limited for the overall systemic effects of the seven active ingredients working together as a single fixed-dose combination across the range of its intended uses. Subgroup findings are uncertain in many areas, meaning it is not always clear how the reported outcomes relate to patients based on varying degrees of symptom intensity, age, or underlying deficiency status.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Celol-D3 (FAQ)

Q: Why is Celol-D3 sometimes prescribed for osteoporosis or osteomalacia?

Regulatory documents indicate that the active component, calcitriol, is officially used in the management of metabolic bone diseases like osteoporosis and osteomalacia. Regulatory descriptions indicate its intended purpose is to increase the body's absorption of calcium and support the process of bone mineralisation. This action is relevant for maintaining skeletal health.

Q: What serious side effects are listed in regulatory documents for Celol-D3?

The principal safety concern documented in official product information is severe or uncontrolled hypercalcemia (high calcium levels in the blood), which is classified as a Serious Adverse Reaction. Chronic hypercalcemia may lead to long-term consequences such as generalized vascular calcification and nephrocalcinosis (calcium deposits in the kidneys). The safety profile necessitates the close monitoring of blood levels to manage these potential risks.

Q: Are there any food groups that affect Celol-D3 absorption?

Official information notes that the efficacy of the active component Calcitriol is supported by an adequate daily intake of calcium from foods or supplements. Patients may find information regarding the need to adjust their overall dietary intake of calcium and phosphorus. Always refer to the official product labeling for detailed guidance.

Q: Why is Celol-D3 often referred to as a fat-soluble vitamin?

Vitamin D, which includes the active component Calcitriol, is biologically classified as a fat-soluble vitamin. Due to this classification, the vitamin is known to use dietary fat for absorption and transport in the body. This is a characteristic of the drug's core chemical structure.

Q: Why is Celol-D3 sometimes combined with calcium?

The combination is formulated with the intent of providing skeletal support. The active component Calcitriol helps the body to use more of the calcium from foods or supplements by promoting absorption. The components are combined to ensure both key nutrients are available to support bone formation and maintenance.

Q: What is the difference between Vitamin D2 and D3 in official documents?

In official sources, Vitamin D3 (cholecalciferol) is defined as the form naturally synthesized in the skin from sunlight or consumed from animal-based foods. Vitamin D2 (ergocalciferol) is derived mainly from plant sources and yeast. Both forms must be chemically converted in the body to become the most active form, Calcitriol.

Q: How quickly does Celol-D3 start working to raise Vitamin D levels?

Pharmacokinetic data shows that following oral administration of the active component Calcitriol, the concentration peaks in the blood generally within 3 to 6 hours. The pharmacological activity of a single dose is then expected to last for about 3 to 5 days. This provides context for the drug's action over time.

Q: What distinguishes Celol-D3 Plus Tablet from the standard Celol-D3 Granules?

Official information indicates that the specific composition varies between different product forms in the Celol D3 family. Some products are formulated with the active metabolite Calcitriol, while others, such as a Plus Tablet or Granules, may contain Cholecalciferol (Vitamin D3) and Elemental Calcium. The specific active ingredients for any formulation are detailed in the official product information.

Q: Are there official studies examining Celol-D3's effect on muscle weakness or fatigue?

Studies related to the core components have explored outcomes related to muscle weakness. Official information notes that low levels of Vitamin D are associated with muscle pain and weakness. The intended function of the product includes elevating calcium and phosphate levels to support bone and neuromuscular function.

Q: Is it necessary to take Celol-D3 with a meal to ensure proper absorption?

The active component Calcitriol is generally advised to be taken once a day or once every other day with or without food. Some formulations containing Vitamin D3 (Cholecalciferol) may be known to be better absorbed after a meal. Specific product labels contain information regarding administration with or without food.

Q: Does Celol-D3 contain lactose, gluten, or other common allergens?

The official labeling for Celol-D3 lists all inactive ingredients and excipients. Official guidance notes that some vitamin D formulations may contain ingredients such as peanut or soybean oil. The specific excipients and allergens are listed in the official patient information leaflet (PIL) or regulatory label for the formulation being used.

Q: Are there documented uses of Celol-D3 beyond bone and vitamin deficiency?

FDA-approved indications for the active component Calcitriol include the management of low calcium (hypocalcemia) in patients on chronic renal dialysis. It is also approved for managing secondary hyperparathyroidism and hypocalcemia in patients with hypoparathyroidism. These are specific uses documented in regulatory materials.

Q: What is the maximum daily intake of Vitamin D3 that official bodies typically cite as safe?

The NIH Office of Dietary Supplements cites the Tolerable Upper Intake Level (UL) for Vitamin D (Cholecalciferol/D3), which is the maximum amount unlikely to cause adverse effects. This level is established by age; for adults aged 19-70, this level is cited as 100 mcg (4,000 IU) per day.

How should Celol-D3 be stored and disposed of?

How to Store and Dispose of Celol-D3

The official labeling for this medicine specifies storage and disposal requirements necessary to maintain product integrity and ensure safety, based on government regulatory standards.

Official Storage Conditions

Requirement	Standard Mandated by Regulatory Documents
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F)
Protection	Must be protected from light and moisture to prevent degradation of the capsules and components
Container	Store in the original container and keep the container tightly closed
Handling Restriction	Do not refrigerate or freeze

All medicines must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Celol-D3 must be disposed of according to local regulations for pharmaceutical waste. Regulatory guidance prohibits discarding the medicine in household trash or flushing it down a toilet or sink.

Celol-D3